- Opinion
- [Reporter's view] Are you ready to use
- by Lee, Hye-Kyung May 18, 2023 05:45am
- The 'Act on the Safety and Support of Advanced Recycles and Advanced Biomedicines' will be in effect for three years in August. The Advanced Recycled Bio Act prepares a system for securing the safety of advanced renewable medicine, provides a plan for technological innovation, and practical use, and stipulates the necessary matters to secure
- Opinion
- [Reporter’s View] Bitter ERPs following spin-offs and sales
- by Eo, Yun-Ho May 17, 2023 05:38am
- The operation of Early Retirement Program (ERP) schemes following sales of business units has been frequenting as an issue in the pharmaceutical industry. Although the spin-off and sales by multinational pharmaceutical companies aim at ‘separation of innovation and legacy, ‘this premise of ‘selecting and focusing’ on its strengths ine
- Opinion
- [Reporter's view] AI drug development, should face reality
- by Hwang, Jin-joon May 16, 2023 05:39am
- "Artificial intelligence (AI) drug development will be useful, but there is a problem with only talking too much hope. Domestic AI drug development is still at an early stage, so more R&D is needed." These are the words the representative of an AI drug development company attending a recently held event related to digital healthcare threw to
- Opinion
- [Reporter’s View] MSD Korea ‘Calm before the storm’
- by Jung, Sae-Im May 11, 2023 05:46am
- “There were rumors from a month ago, but they proved true. I am at a loss for words at the announcement that the department will be closed down." With the news that MSD Korea’s blockbuster antidiabetic treatment ‘Januvia Series’ will be handed over to Chong Kun Dang, the employees at MSD Korea received the crushing news that the compa
- Opinion
- [Reporter's View] Suspension of drug price cut
- by Kim, Jin-Gu May 8, 2023 05:41am
- The price of Forxiga, an SGLT-2 diabetes drug, remains unchanged despite the release of a generic version. AstraZeneca applied for suspension of drug price cut execution along with an administrative lawsuit, and the court accepted it. AstraZeneca cited the reason that Forxiga's indications include not only diabetes but also heart failure and
- Opinion
- [Reporter's View] Patent expired original
- by Lee, Tak-Sun May 3, 2023 05:38am
- For original drug patents that have expired, the upper limit is adjusted under the authority of the Ministry of Health and Welfare when a generic drug with the same product appears. Original drugs will be reduced to 70% of the previous price for one year, and from the second year onwards, the price will drop to the same 53.55% level as gener
- Opinion
- [Reporter's View] Rise of patients and concerns
- by Eo, Yun-Ho Apr 18, 2023 05:37am
- Medicine is a product with strong public goods characteristics. It is a means of curing human diseases and maintaining health. In Korea, national health insurance is also applied. Another fact is that it is the company that makes and sells it. The purpose is to make a profit. Pharmaceuticals are high-value-added products that can make a lo
- Opinion
- [Reporter's View] Preferential price for innovative drugs
- by Lee, Jeong-Hwan Apr 6, 2023 05:54am
- Second Vice Minister of Health and Welfare Park Min-soo promised the National Assembly that he would make a rule that gives preferential prices to medicines made by innovative pharmaceutical companies over other medicines. This is in the same context as Vice Minister Park Min-soo clearly expressed his will to improve the drug pricing system,
- Opinion
- [Reporter’s View] Accepting drugs used by very few patients
- by Eo, Yun-Ho Mar 30, 2023 05:41am
- It's the same 'cancer', but different. So how should we regard these new anticancer drugs that target only a very few among all patients that have the same type of cancer? The cancer types that we commonly refer to, such as liver cancer, stomach cancer, and lung cancer are just major categories used, and the specific condition of each pat
- Opinion
- [Reporter's view] The goal of global new drug development
- by Hwang, Jin-joon Mar 28, 2023 05:54am
- When the government announced the 'Third Five-Year Comprehensive Plan to Foster and Support the Pharmaceutical Bio Industry', it was emphasized that it would create three new blockbuster drugs that record global sales of more than 1 trillion won by 2030. For this purpose, strategic R&D investment was selected as a key task. In the development
